Yttrium-90

Phase 1Radiopharmaceutical

UUniversity Health Network, Toronto

Yttrium-90 is one of 63 small molecule programs targeting Liver Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Liver CancerPreclinical

Active, not recruiting

Hepatocellular CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

1 2

Hepsera

Coreg

2 4

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Opdivo

Bristol-Myers Squibb

Preclinical

2 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Stereotactic Body Radiation Therapy (SBRT)

NCT04518748

Q2 2034

Phase 1/2Recruiting

Liver Cancer

NCT06725121

Clinical

Trials by Indication[1]

Liver Cancer2 trials

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn·UUniversity of Southern California·N/A·NCT03300401

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 1/2·NCT06725121·48 enrolled

Stereotactic Body Radiation Therapy (SBRT)1 trial

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04518748·70 enrolled

Hepatocellular Carcinoma1 trial

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Completed·NNorthwestern University·Phase 1·NCT00846131·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Yttrium-90. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yttrium-90 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yttrium-90. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: UUniversity Health Network, Toronto

Yttrium-90

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2034

Trials by Indication[1]

Liver Cancer2 trials

Stereotactic Body Radiation Therapy (SBRT)1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News